Task Force

 

Editorial: Outcomes For Alzheimer's Trials,
B. Vellas (France)

Clinical Relevance on Alzheimer?s Disease Endpoints
C. Sampaio (Portugal)

Outcomes for Disease Modifying Trials
G. Wilcock (United-Kingdom)

What Can We Learn from the FACIT Trial: A Randomized, Double Blind, Controlled Trial,
J. Durga, M.P.J. van Boxtel, E.G. Schouten, F.J. Kok, J. Jolles, M.B. Katan, P. Verhoef (The Netherlands)

Outcome for Secondary Preventive Trials (in Mild Cognitive Impairment)
E. Salmon (Belgium)

Measuring Cognitive Change in Alzheimer?s Disease Clinical Drug Trials
J.E. Harrison (United-Kingdom)

Six and 18-Month Changes in Mild to Moderate Alzheimer?s Patients Treated with Acetylcholinesterase Inhibitors: What Can We Learn for Clinical Outcomes of Therapeutic Trials?
F. Cortes, F. Portet, J. Touchon, B. Vellas and REAL.FR Group (France)

Long-Term Changes in ADAS-cog: What Is Clinically Relevant for Disease Modifying Trials in Alzheimer?
B. Vellas, S. Andrieu, C. Cantet, J.F. Dartigues, S. Gauthier and the REAL.FR Group (France, Canada)

Caregiver Outcomes in Disease Modifying Trials
F.R.J. Verhey, M.E. de Vugt, P. Aalten, M.J. Vernooij-Dassen, E.J. Byrne, P. Robert (The Netherlands, United-Kingdom, France)

Neuropsychiatric Outcome for Clinical Trials
P. Robert, F.R.J. Verhey, P. Aalten, F. Cortes, E.J. Byrne (France, The Netherlands, United-Kingdom)

Neuroimaging Outcomes for Clinical Trials
G.B. Frisoni, A. Caroli (Italy)

Assessing Health Economic Outcome in Alzheimer?s Disease Clinical Trials
L. Jönsson (Sweden)

Outcomes for Clinical Trials in Mild-to-Moderate Dementia to Evaluate Drugs with Presumably Symptomatic Effects
L. Frölich (Germany)

Biomarkers for Disease Modification Trials? The Innovative Medicines Initiative and AddNeuroMed
S. Lovestone, P. Francis, K. Strandgaard On behalf of the AddNeuroMed collaborative group (United-Kingdom)